This brand name is authorized in Nigeria.
The drug BIZORAN contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
864V2Q084H - AMLODIPINE BESYLATE
|
|
Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle. |
|
2
|
UNII
6M97XTV3HD - OLMESARTAN MEDOXOMIL
|
|
Olmesartan medoxomil is a potent, orally active, selective angiotensin II receptor (type AT1) antagonist. It is expected to block all actions of angiotensin II mediated by the AT1 receptor, regardless of the source or route of synthesis of angiotensin II. The selective antagonism of the angiotensin II (AT1) receptors results in increases in plasma renin levels and angiotensin I and II concentrations, and some decrease in plasma aldosterone concentrations. |
|
This drug has been approved in Nigeria as follows:
| Identifier | Form | Presentation | Description | Approval |
|---|---|---|---|---|
| B4-7629 | Tablet | BIZORAN TABLETS TAB 5 mg; 20 mg 310 | BIZORAN TABLETS AMLODIPINE BESILATE BP EQUIVALENT TO AMLODIPINE 5MG, OLMESARTAN MEDOXOMIL BP 20MG AMLODIPINE BESILATE BP EQUIVALENT TO AMLODIPINE 5MG, OLMESARTAN MEDOXOMIL BP 20MG, LUDIPRESS, CROSCARMELLOSE SODIUM, HYDROXYPROPYL CELLULOSE, MAGNESIUM STEARATE, OPADRY II (BLUE), CARNAUBA WAX, PURIFIED WATER B4-7629 Drugs Imported Products 310 POM 1 27/10/2022 STADARD GENERICE LTD, ABOR CLOSE, OFF FOLA AGORO ST, YABA LAGOS LAGOS 12799144 stdgenerics@yahoo.com BEXIMCO PHARMACEUTICALS LTD, 19, DHANMONDI R/A, ROAD NO. 7, DHAKA-1205, BANGLADESH, Bangladesh | 26/04/2023 |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| C09DB02 | Olmesartan medoxomil and amlodipine | C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09D Angiotensin II antagonists, combinations → C09DB Angiotensin II antagonists and calcium channel blockers |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| NG | Registered Drug Product Database | B4-7629 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.